RenovoRx Reports First Quarter 2023 Financial Results and Operational HighlightsBusiness Wire • 05/15/23
RenovoRx to Participate in the Aegis Capital Virtual Conference on May 3, 2023Business Wire • 04/28/23
RenovoRx Appoints Former Chief Medical Officer of Schering-Plough, Robert J. Spiegel, MD, FACP, to Board of DirectorsBusiness Wire • 04/27/23
RenovoRx Presenting Phase III Clinical Trial Interim Analysis Data of the TIGeR-PaC Study at American Association for Cancer Research Annual Meeting Underway in Orlando, FloridaBusiness Wire • 04/14/23
RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical OperationsBusiness Wire • 04/11/23
RenovoRx, Inc. Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesBusiness Wire • 03/30/23
RenovoRx Announces Positive New Data from Phase III Clinical Trial Interim Analysis: 60% Survival Benefit and Fewer Side Effects than Systemic ChemotherapyBusiness Wire • 03/30/23
RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGemTM as a Treatment Option for Locally Advanced Pancreatic CancerBusiness Wire • 03/08/23
RenovoRx Reports Full Year 2022 Financial Results and Achievement of Important Phase III Clinical Study MilestoneBusiness Wire • 03/02/23
RenovoRx to Present at the Sequire Biotechnology Virtual Conference on February 2, 2023Business Wire • 01/25/23
RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem™ Supports Potential for RenovoTAMP® Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and Decrease Side Effects of Pancreatic Cancer TreatmentBusiness Wire • 01/18/23
RenovoRx Strengthens Intellectual Property (IP) Portfolio with Eighth US PatentBusiness Wire • 01/05/23
RenovoRx Announces Acceptance of Four Clinical Data Abstracts at the 2023 ASCO Gastrointestinal Cancers (ASCO GI) SymposiumBusiness Wire • 12/15/22
RenovoRx Announces Presentations at the Advanced Interventional Management Symposium (AIMsymposium) Highlighting its Innovative RenovoTAMP® Therapy Platform for Targeted Treatment of CancersBusiness Wire • 11/17/22
RenovoRx to Participate in ROTH Capital Deep Dive Webinar on October 27, 2022 at 1:00 P.M. ETBusiness Wire • 10/21/22
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology (CIO) Highlighting its Innovative Therapy Platform for Targeted Treatment of Pancreatic CancerBusiness Wire • 09/28/22
RenovoRx to Participate in the H.C. Wainwright 24th Annual Global Investment Conference, September 12-14, 2022Business Wire • 09/07/22